Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk — Stella

Home/End-Stage Renal Disease/CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

View on ClinicalTrials.gov

Recruiting

Back to End-Stage Renal Disease trials

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Peking University Health Science Center (PKUHSC), Beijing, Changping

Key details

Phase

Early testing / Safety & dosing

Sponsor

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Enrollment target

~90 participants

Started

June 2025

Primary completion

December 2027

Age range

16 Years – 85 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.